טוען...
Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
ErbB2, a member of the ErbB family of receptor tyrosine kinases, is an essential player in the cell’s growth and proliferation signaling pathways. Amplification or overexpression of ErbB2 is observed in ∼30% of breast cancer patients, and often drives cellular transformation and cancer development....
שמור ב:
| הוצא לאור ב: | Cell Death Dis |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Publishing Group UK
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5833446/ https://ncbi.nlm.nih.gov/pubmed/29352243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-017-0067-7 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|